Alkem Laboratories is currently trading at Rs. 3781.80, down by 51.75 points or 1.35% from its previous closing of Rs. 3833.55 on the BSE.
The scrip opened at Rs. 3815.55 and has touched a high and low of Rs. 3815.55 and Rs. 3747.70 respectively. So far 2493 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3946.45 on 02-Sep-2021 and a 52 week low of Rs. 2544.25 on 24-Mar-2021.
Last one week high and low of the scrip stood at Rs. 3895.60 and Rs. 3746.70 respectively. The current market cap of the company is Rs. 45076.01 crore.
The promoters holding in the company stood at 58.84%, while Institutions and Non-Institutions held 18.99% and 22.17% respectively.
Alkem Laboratories has received approval to close the operations at Beta Block (Unit II) manufacturing facility located at Baddi. The Beta Block (Unit-II) manufacturing facility at Baddi mainly catered to domestic market for Injections and was significantly underutilized. To avoid operating expenditure in Baddi, it is decided to discontinue the manufacturing operations at this facility, pursuant to the date of closure this facility shall be used as a warehouse.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: